Get ready for the DTC onslaught for this dog of a drug:
The device has been faring very poorly. Sales last year were just a few million dollars and Pfizer sales reps have carped about being unable to meet quotas. Recent market share data shows Exubera losing still more ground.
Of course, Pfizer will likely annoy some doctors and politicians, who don’t fancy ads that encourage patients to demand expensive treatments. Exubera costs about $600 more than injectable insulin. But who cares if insurers pay for that bong-like experience?
(via PharmaGossip)
